CompanyOTLKNasdaqIselin, NJ

Outlook Therapeutics, Inc.

Outlook Therapeutics develops LYTENAVA, an ophthalmic formulation of bevacizumab for wet age-related macular degeneration.

SEC EDGAR ClinicalTrials.gov

8-KSep 30Latest SEC filing

Aug 27Latest story

August 2026

Outlook Therapeutics names Kevin Lundquist as new CFO

Aug 27PeopleOutlook Therapeutics, Inc.

Outlook Therapeutics prices $55 million stock and warrant offering

Aug 14Financingbevacizumab-vikg Outlook Therapeutics, Inc.

Outlook Therapeutics details LYTENAVA US launch prep in Q3 FY2026 update

Aug 14Quarterly updatebevacizumab-vikg Outlook Therapeutics, Inc.

Outlook Therapeutics posts Phase 3 results for ONS-5010 in wet AMD trial

Aug 3Trial updatebevacizumab Outlook Therapeutics, Inc.

July 2026

Outlook Therapeutics wins FDA approval for Lytenava in wet AMD

Jul 24Regulatory decisionbevacizumab-vikg Outlook Therapeutics, Inc.

Outlook Therapeutics grants options and bonuses tied to ONS-5010 BLA progress

Jul 23Peoplebevacizumab Outlook Therapeutics, Inc.

Outlook Therapeutics posts NORSE THREE results for ONS-5010 in retinal disorders

Jul 17Trial updatebevacizumab Outlook Therapeutics, Inc.

June 2026

Outlook Therapeutics posts NORSE EIGHT phase 3 results for ONS-5010 in wet AMD

Jun 30Trial updatebevacizumab Outlook Therapeutics, Inc.